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and those without night pain (WN-group) and core temperature
of theirs was compared. Statistical analysis was performed using
repeated measures ANOVA and p value less than 0.05 was
considered as statistically signiﬁcant.
Results: Core temperature of both the knee and the sternum
decreased at around 5 am according to circadian rhythm.
Core temperature of the knee was signiﬁcantly lower than that of
the sternum in KOA. On the other hand, such difference was not
seen in control knees.
Core temperature of the knee between N-group and WN-group
was not different.
Conclusions: We revealed the lower core temperature of the
knee in end-stage KOA. This indicated existence of blood ﬂow
disturbance in OA knees. Our data supports decreased bone
perfusion in KOA exhibited with perfusion MRI. Elevated bone
marrow pressure measured with invasive technique was also
reported as one possible mechanisms of KOA pain and it might
related to blood ﬂow disturbance, though inconsistent results was
reported about bone marrow pressure.
In the present study, we ﬁrstly reported blood ﬂow disturbance in
KOA by measuring core temperature. We only dealt end-stage OA
patients in this study, but this non-invasive method might be useful
in monitoring KOA status.
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Purpose: This was a randomized controlled trial (RCT) with exten-
sion and open-label re-treatment phases to determine if single or
repeated intra-articular injections of Gel-200 are safe and effective
in subjects with symptomatic knee osteoarthritis.
Methods: Subjects completing Week 13 in SI-6606/01 RCT were
offered enrollment in extension phase, evaluating durability of
responses relative to initial baseline for up to 13 weeks. If and
when subjects qualiﬁed for re-treatment based on WOMAC pain
subscore ≥40 mm in treated knee, they received a single injection
of Gel-200 at Week R0 (open-label baseline). Survival analyses
were conducted in Kaplan-Meier and Cox proportional hazard
models to compare time to re-treatment eligibility using 2 different
pre-speciﬁed endpoints: (A) WOMAC pain subscore ≥40 mm; and
(B) WOMAC Pain ≥40 mm and improvement from baseline <20
mm.
Results: Of 350 completing SI-6606/01; 258 subjects entered
extension: 199 subjects were re-treated with Gel-200; 74 ana-
lyzed for continued effectiveness. Kaplan-Meier estimates showed
a statistically signiﬁcant advantage for Gel-200 in both Endpoints
A (p=0.049) and B (p=0.034). [Table] Median times to re-treatment
eligibility were 6.3 weeks for subjects initially receiving Gel-200
compared with 3.7 weeks for PBS by (A), and 13.1 vs 6.0 weeks by
Endpoint (B). In Cox proportional hazard models, Gel-200 showed
statistically signiﬁcant advantages in durability of response, using
treatment, age, and baseline WOMAC pain subscore as covariates
for Endpoints A (p=0.019) and B (p=0.027). All subjects receiv-
ing open label Gel-200 demonstrated improvement from Week
R0 baseline in WOMAC scores (pain, stiffness, function, total),
global assessments (subject, physician) (P<0.0001); incidence of
adverse events [AEs] within 24 hours of injection were comparable
to those observed in initial RCT. There were no allergic reactions
or unanticipated device-related AE. Serious AE occurred in 6
subjects, none related to the study injection.
Survival Analysis - Kaplan-Meier Estimates
Weeks post injection Endpoint A Endpoint B
in the SI-6606/01 study (p=0.049) (p=0.034)
Gel-200 PBS Gel-200 PBS
(N=247) (N=128) (N=247) (N=128)
Week 1 1.000 1.000 1.000 1.000
Week 3 0.952 0.941 0.961 0.942
Week 6 0.522 0.390 0.616 0.500
Week 9 0.473 0.355 0.560 0.441
Week 13 0.419 0.346 0.514 0.406
Week 16 (Week 3 in Extension phase) 0.292 0.264 0.387 0.342
Week 19 (Week 6 in Extension phase) 0.292 0.264 0.387 0.342
Week 22 (Week 9 in Extension phase) 0.280 0.264 0.375 0.342
Week 26 (Week 13 in Extension phase) 0.280 0.237 0.375 0.317
Conclusions: Together, these data support the efﬁcacy and dura-
bility of response of a single intraarticular injection of Gel-200 over
13 weeks as treatment for knee osteoarthritis. This study also
demonstrated that repeat treatment of Gel-200 was well tolerated.
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Purpose: To assess the long-term safety and effectiveness of
tapentadol extended release (ER), a novel centrally acting anal-
gesic in development for the management of moderate to severe
chronic pain, over 1 year of treatment in patients with chronic low
back or osteoarthritis pain.
Methods: Patients were randomized 4:1 to receive controlled,
adjustable, oral bid doses of tapentadol ER 100-250 mg or oxy-
codone HCl controlled release (CR) 20-50 mg. In order to establish
an optimal therapeutic dose, deﬁned as a dose providing a bal-
ance of efﬁcacy and tolerability, patients could titrate their doses in
increments of 50-mg bid tapentadol ER or 10-mg bid oxycodone
HCl CR during a 51-week maintenance period. Safety was as-
sessed for all patients who received at least 1 dose of study
medication.
Results: Patients received tapentadol ER (n = 894) or oxycodone
CR (n = 224). The mean (standard deviation) and median most
frequently used daily doses were 352.2 (132.43) mg and 400
mg with tapentadol ER and 56.8 (30.07) mg and 40 mg with
oxycodone HCl CR. Patients who received tapentadol ER and
oxycodone CR took the most frequently used dose for a median
duration of 133.5 and 45.0 consecutive days, respectively. Patients
in the oxycodone CR group discontinued treatment earlier than
patients in the tapentadol ER group; in the ﬁrst 4 weeks of
the study, approximately 40% of patients in the oxycodone CR
group discontinued treatment compared with approximately 20%
of patients in the tapentadol ER group. The percentage of patients
who discontinued because of adverse events (AEs) during the
